FDA approves Orca Bio’s cell therapy to improve transplant outcomes
FDA approves Orca Bio’s cell therapy to improve transplant outcomes — Endpoints News coverage of biopharma industry developments.
Orca Bio
Private
Orca Bio is a clinical-stage cell therapy company developing high-precision, allogeneic cell therapies for cancer and autoimmune diseases.
Company Info
Sector:Cell Therapy
Headquarters:Menlo Park, California, United States
Founded:2014
Website:orcabio.com/
Total Funding:>$300M
Upcoming Milestones & Key Dates
2026-Q4
Commercial
Tregzi commercial launch
Clinical Development Pipeline
Tregzi (ORCA-T)
Target: Regulatory T cellsORCA-201
Target: CD20ORCA-202
Target: CD19Recent News
Orca Bio Cell Therapy Gets Landmark FDA Nod for New Kind of Living Medicine
Orca Bio Cell Therapy Gets Landmark FDA Nod for New Kind of Living Medicine — MedCity News coverage of biopharma industry developments.
Orca Bio Cell Therapy Gets Landmark FDA Nod for New Kind of Living Medicine
Orca Bio Cell Therapy Gets Landmark FDA Nod for New Kind of Living Medicine (MedCity News.)
Leadership Team
Ivan Dimov
Chief Executive Officer
Dave Fanning
Chief Financial Officer
Justin Eyquem
Chief Scientific Officer